(UroToday.com) Testicular cancer is the most common malignancy among men aged 20-39 years, and testicular cancer survivors are at high risk for short-term and long-term cisplatin-based chemotherapy side effects. Hearing loss, a common cisplatin toxicity, is permanent and irreversible. Although pure-tone audiometry is the gold standard to evaluate hearing loss, patient-reported outcomes are more practical and cost-effective. However, no data exist on factors associated with discrepancies between patient-reported and audiometrically-defined hearing loss in adult-onset cancer survivors after cisplatin-based chemotherapy, and few comprehensive assessments of factors associated with audiometrically-defined hearing loss have been conducted. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Shirin Ardeshir-Rouhani-Fard and colleagues presented data of their study assessing patient-reported outcomes versus audiometric assessments.